Correlation between HPV status via in situ hybridization testing on genital squamous papillomas and risk for cervical dysplasia or other anogenital HPV-related complications: A case-control study To the Editor: Human papillomavirus (HPV) is a cause of cervical cancer and condylomata acuminata. [1] [2] [3] Though condylomata are often recognized clinically, specimens submitted for histopathologic interpretation can be tested for HPV serotypes via in situ hybridization (ISH). 4 Our study evaluated the relationship between tissue HPV expression in genital squamous papillomas and cervical or other anogenital HPV-related complications.
We retrospectively reviewed all skin biopsies of genital squamous papillomas that were serotyped for low-and high-risk HPV strains by ISH in women from 2004 through 2014 at our institution. Results were tabulated based on HPV serotype, Papanicolaou smear abnormalities (including atypical cells of undetermined significance, low-grade squamous intraepithelial lesion, high-grade squamous intraepithelial lesion, cervical intraepithelial neoplasia I-III) and other HPV-related diagnoses (eg, anal intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia). Statistical analysis included 2-tailed Fisher's exact test, t test, Chi square, and Anova analysis, and a P value of #.05 was considered statistically significant.
We included 147 specimens from 243 patients. (Table II) . No specimen was positive for both low-and highrisk HPV. No difference in Papanicolaou smear abnormalities was found when comparing patients whose specimens tested positive for any type of HPV with those whose specimens tested negative (35% vs 34%, P ¼ .94) or when comparing patients whose specimens tested positive for low-risk HPV with those that tested positive for high-risk HPV (38% vs 14%, P ¼ .19). Lower rates of other anogenital HPVrelated complications were found in patients with HPV-positive compared with patients with HPVnegative skin specimens (7% vs 17%, P ¼ .08). Further subgroup testing revealed no differences in anogenital HPV-related complications in highversus low-risk HPV types (14% vs 6%, respectively; P ¼ .39). One patient was found to have evidence of urothelial carcinoma in situ (n ¼ 1) on vaginal Papanicolaou smear and had an HPV-negative condyloma.
The average time between abnormal Papanicolaou smear and HPV ISH testing of skin biopsies did not differ between those testing positive and negative for any HPV serotype (Table II ). In the group that had negative results for HPV ISH testing of skin specimen, 17% had abnormal Papanicolaou smears found after the skin biopsy was obtained. For those with positive HPV ISH test results, 19% of abnormal Pap smears were found after and 24% were found concurrent with the skin biopsy. In our study, over half of condylomata tested negative for HPV by ISH. When positive, almost 90% showed low-risk HPV serotypes, which supports previous data. 4 There was no correlation between the identification of HPV in condylomata and prior or future Pap smear abnormalities. Patients with skin specimens testing positive for high-risk HPV serotypes did not correlate with risk for cervical dysplasia or other anogenital HPVrelated complications. These findings suggest a lack of utility of tissue HPV testing on condylomata for predicting cervical or anogenital HPV-related complications.
Limitations of our study include retrospective study design, relatively short follow-up durations, and few cases of condylomata testing positive for high-risk HPV, which thus limited study power. While validation from larger studies is required, these data may contribute to discussions regarding appropriate-use criteria for HPV ISH testing on genital squamous papillomas. Funding sources: None.
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